Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,139 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo solution Clear all
Recruiting Phase 1Phase 2 Interventional

PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

NCT07101640
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD), Premature Births, Critical Illness
Interventions
montelukast 4 mg granule, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
7 Days to 28 Days
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Little Rock, Arkansas • Amherst, Massachusetts • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 30, 2026, 3:50 PM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blueberries and Exercise Inflammation

NCT05184855
View directory record Official record
Conditions
Muscular Injury
Interventions
Blueberry, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 30, 2026, 3:50 PM EDT
Not yet recruiting Phase 2 Interventional

Amino Acids for Cardiac Surgery Associated AKI

NCT07001098
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Amino Acids, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 30, 2026, 3:50 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

NCT05547438
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
NTS-104 TRIS, Placebo
Drug
Lead sponsor
NeuroTrauma Sciences, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Grape Impact on Human Gut Microbiome

NCT07797803
View directory record Official record
Conditions
Gut Microbiomes
Interventions
Grape Powder, Placebo Powder
Dietary Supplement · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
OPA-6566, Placebo, Latanoprost
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Artesia, California • Glendale, California • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224560
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 30, 2026, 3:50 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT07625280
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Xywav, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

NCT04206605
View directory record Official record
Conditions
Angioedema
Interventions
Placebo, Lanadelumab
Other · Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 30, 2026, 3:50 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

NCT05740280
View directory record Official record
Conditions
Healthy Volunteers
Interventions
iCP-NI, Placebo
Drug
Lead sponsor
Cellivery Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 30, 2026, 3:50 PM EDT
Terminated Not applicable Interventional Results available

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT02517996
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 30, 2026, 3:50 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

NCT05952986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB825 or Placebo in subcutaneous route, FB825 in intravenous route
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

NCT00533091
View directory record Official record
Conditions
DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
MEDI-545, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Whittier, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction

NCT01524913
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction, Pain, Arthrocentesis
Interventions
Hyaluronic acid, Corticosteroid, Lactated Ringers
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Cinncinati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 30, 2026, 3:50 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

NCT02045888
View directory record Official record
Conditions
Muscle Tear
Interventions
ADRCs prepared by investigational Celution Device, Placebo
Device · Biological
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Combination With Irinotecan- Erbitux

NCT00594984
View directory record Official record
Conditions
Metastatic Colorectal Cancer (MCRC)
Interventions
Cetuximab, Irinotecan, Brivanib, Brivanib Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression

NCT03006393
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 30, 2026, 3:50 PM EDT